AR006664A1 - Formulacion de liberacion extendida de un inhibidor de trombina soluble en agua para administracion parenteral, proceso para su preparacion, metodo paraprofilaxis y/o tratamiento del tromboembolismo arterial y/o venoso y uso de un inhibidor de trombina - Google Patents

Formulacion de liberacion extendida de un inhibidor de trombina soluble en agua para administracion parenteral, proceso para su preparacion, metodo paraprofilaxis y/o tratamiento del tromboembolismo arterial y/o venoso y uso de un inhibidor de trombina

Info

Publication number
AR006664A1
AR006664A1 ARP970101517A ARP970101517A AR006664A1 AR 006664 A1 AR006664 A1 AR 006664A1 AR P970101517 A ARP970101517 A AR P970101517A AR P970101517 A ARP970101517 A AR P970101517A AR 006664 A1 AR006664 A1 AR 006664A1
Authority
AR
Argentina
Prior art keywords
inhibitor
arterial
thromboembolism
release formulation
extended release
Prior art date
Application number
ARP970101517A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR006664A1 publication Critical patent/AR006664A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una formulación de liberación extendida de un inhibidor de trombina soluble en agua para la administración parental que comprende a un inhibidor detrombina que es melagatran, inogatran o su sal soluble en agua fisiologicamente aceptable y un aditivode ciclodextrina soluble en agua para extender laliberación del inhibidor de trombina, proceso para prepararla, método de profilaxis y/o tratamiento del tromboembolismo arterial y/o venoso y uso delinhibidor de trombina.
ARP970101517A 1996-04-24 1997-04-15 Formulacion de liberacion extendida de un inhibidor de trombina soluble en agua para administracion parenteral, proceso para su preparacion, metodo paraprofilaxis y/o tratamiento del tromboembolismo arterial y/o venoso y uso de un inhibidor de trombina AR006664A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9601556A SE9601556D0 (sv) 1996-04-24 1996-04-24 New pharmaceutical formulation of a thrombin inhibitor for parenteral use

Publications (1)

Publication Number Publication Date
AR006664A1 true AR006664A1 (es) 1999-09-08

Family

ID=20402321

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970101517A AR006664A1 (es) 1996-04-24 1997-04-15 Formulacion de liberacion extendida de un inhibidor de trombina soluble en agua para administracion parenteral, proceso para su preparacion, metodo paraprofilaxis y/o tratamiento del tromboembolismo arterial y/o venoso y uso de un inhibidor de trombina

Country Status (6)

Country Link
AR (1) AR006664A1 (es)
AU (1) AU2719597A (es)
ID (1) ID17334A (es)
SE (1) SE9601556D0 (es)
WO (1) WO1997039770A1 (es)
ZA (1) ZA973062B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9802938D0 (sv) 1998-09-01 1998-09-01 Astra Ab Improved stability for injection solutions
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
SE9900070D0 (sv) 1999-01-13 1999-01-13 Astra Ab New use
FR2793418B1 (fr) * 1999-05-11 2001-07-27 Synthelabo Formulations galeniques d'agents antithrombotiques pour administration sous-cutanee
SE9902202D0 (sv) 1999-06-10 1999-06-10 Astra Ab Production of aggregates
SE0001803D0 (sv) 2000-05-16 2000-05-16 Astrazeneca Ab New compounds i
GB0014136D0 (en) * 2000-06-10 2000-08-02 Astrazeneca Ab Combination therapy
GB0014134D0 (en) * 2000-06-10 2000-08-02 Astrazeneca Ab Combination therapy
PE20020300A1 (es) 2000-08-22 2002-05-10 Pharmacia Corp Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
US6462021B1 (en) 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
SE0101762D0 (sv) * 2001-05-18 2001-05-18 Astrazeneca Ab New use
SE0201659D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
SE0201661D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab New salts
SE0201658D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab Immediate release pharmaceutical formulation
DK1569912T3 (en) 2002-12-03 2015-06-29 Pharmacyclics Inc 2- (2-hydroxybiphenyl-3-yl) -1h-benzoimidazole-5-carboxamidine derivatives as factor VIIa inhibitors.
TW200827336A (en) 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms
EP2836206A4 (en) * 2012-04-10 2015-11-04 Rubicon Res Private Ltd PHARMACEUTICAL FORMULATIONS WITH CONTROLLED RELEASE OF DIRECT THROMBINS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
DK93993D0 (da) * 1993-08-17 1993-08-17 Finn Molke Borgbjerg Anvendelse af 2-hydroxypropyl-beta-cyclodextrin til fremstilling af et systemisk analgetisk opioidpraeparat

Also Published As

Publication number Publication date
WO1997039770A1 (en) 1997-10-30
AU2719597A (en) 1997-11-12
ZA973062B (en) 1997-10-24
SE9601556D0 (sv) 1996-04-24
ID17334A (id) 1997-12-18

Similar Documents

Publication Publication Date Title
AR006664A1 (es) Formulacion de liberacion extendida de un inhibidor de trombina soluble en agua para administracion parenteral, proceso para su preparacion, metodo paraprofilaxis y/o tratamiento del tromboembolismo arterial y/o venoso y uso de un inhibidor de trombina
BG102668A (en) Application of ppar-alpha and prar-gamma antagonist for the treatment of syndrome x
SE9503143D0 (sv) New preparation
WO2002022598A8 (en) Quinolinone derivatives as tyrosine kinase inhibitors
WO2003020202A3 (en) Method for reducing hypertension and heart failure
WO2001093852A3 (en) Method of treating pain using nalbuphine and opioid antagonists
ES2130622T3 (es) Sistema para la administracion transdermica de farmacos.
ATE237330T1 (de) Verabreichung von nikotin im dickdarm zur behandlung von entzündlicher eingeweidenerkrankung
ATE182792T1 (de) Wundheilung
DE69738667D1 (de) Vorbeugung und behandlung von kolonadenom oder kolonmikroadenom mit 6-fluorursodeoxycholsäure
AU4319699A (en) Antimicrobial locks comprising taurinamide derivatives and carboxylic acids and/or salts thereof
WO1999045920A3 (en) The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation
ES2177483T1 (es) Lucha contra la infeccion en sistemas de distribucion.
DE69116380D1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
ES2143809T3 (es) Composicion de eliminacion de comedones queratinicos.
NO931886D0 (no) Anvendelse av aica ribocid-forbindelser for behandling/prevensjon av vevskader som skyldes nedsatt blodstroemning
DE60143078D1 (de) Pax2 zur behandlung von nierenkrankheiten
BR0007452A (pt) Uso de melagatrano ou de um derivado farmaceuticamente aceitável ou pró-droga do mesmo, método de tratamento de inflamação, e, formulação farmacêutica para uso no tratamento de inflamação
Kapil et al. Anti‐complement activity of oleanolic acid: an inhibitor of C3‐convertase of the classical complement pathway
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
AU6383296A (en) Multivalent bovine coronavirus vaccine and method of treating bovine coronavirus infection
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
BR0012661A (pt) Métodos de tratamento e métodos de triagem de drogas
MX9705916A (es) Terapia de combinacion para infeccion por vih usando el inhibidor de proteasa de vih indinavir y el inhibidor de transcriptasa inversa 3tc, opcionalmente junto con azt, ddi, o ddc.
ES2139774T3 (es) Uso de una combinacion de antineoplastones en la preparacion de un medicamento para el tratamiento de la neurofibromatosis.